The mean age of the trial population was 39 years and mean duration of diabetes was 15.7 years
These are not classic drug interactions in the pharmacological sense, but they can influence how comfortable someone feels while adjusting to Semaglutide
Case reports have documented darkening of existing moles, new pigmented lesions, and melanoma diagnosed in users
Participants in the tablet trial lost an average of 13.6% of body weight at 64 weeks, while those in the injection trial lost 14.9% at 68 weeks
Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid this treatment
Food & Drug Administration, FDA Approves New Medication for Chronic Weight Management, November 2023 6 PBS, The many ways new weight loss drugs could transform the economy, June 2024 7 MarketWatch, Obesity drugs next wave: These companies could snag 20% of GLP-1 market, analysts say, August 2024 8 The Minnesota Star Tribune, Analysis finds that after 2 years GLP-1 drugs for weight loss dont justify their price, October 2024 9 PWC, From molecules to milestones: Reinventing for the future of weight loss drugs, October 2024 10 Kaiser Family Foundation KFF Health Tracking Poll, May 2024: The Publics Use and Views of GLP-1 Drugs, Accessed: 01-13-2025 11 The Washington Post, Weight-loss drugs change shopping habits, September 2024 12 Cornell, The No-Hunger Games: How GLP-1 Medicine Adoption is Changing Consumer Food Purchases, December 2024 13 Bloomberg, Ozempic is Making People Buy Less Food, Walmart Says, October 2023
